{"id":390632,"date":"2018-07-05T00:00:00","date_gmt":"2018-07-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreon0034-2018-biopharma-immune-checkpoint-inhibitors-access-and-reimbursement-eu5-2018\/"},"modified":"2026-03-31T10:48:14","modified_gmt":"2026-03-31T10:48:14","slug":"acreon0034-2018-biopharma-immune-checkpoint-inhibitors-access-and-reimbursement-eu5-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreon0034-2018-biopharma-immune-checkpoint-inhibitors-access-and-reimbursement-eu5-2018\/","title":{"rendered":"Immune Checkpoint Inhibitors | Access and Reimbursement | EU5 | 2018"},"content":{"rendered":"<p>Immune checkpoint inhibitors are now at the center of the clinical treatment of metastatic non-small-cell lung cancer (NSCLC). In 2017, the European Commission granted successive approvals to three immune checkpoint inhibitors for bladder cancer: Opdivo, Keytruda, and Tecentriq. In the same year, label expansions were granted to Opdivo for squamous cell carcinoma of the head and neck (SCCHN) and to Tecentriq for NSCLC. As premium-priced immune checkpoint inhibitors enter novel indications and patient populations, payer-imposed reimbursement restrictions and cost-containment strategies will increasingly play a pivotal role in shaping medical oncologists\u2019 prescribing practices and, in turn, determining the commercial success of immune checkpoint inhibitors.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>What are the key driving forces and constraints that influence EU5 payers\u2019 reimbursement decisions for immune checkpoint inhibitors in NSCLC, bladder cancer, and SCCHN?<\/li>\n<li>How do market access and reimbursement policies at the national, regional, and local level shape prescribing preferences for immune checkpoint inhibitors?<\/li>\n<li>How do payers prioritize diminishing budgets\u00a0and control prescribing of immune checkpoint inhibitors?<\/li>\n<li>How do oncologists view emerging immune checkpoint inhibitors, and do they expect to prescribe them? To what extent will EU5 payer policy likely impact the uptake of these novel agents?<\/li>\n<\/ul>\n<p><strong>Product Description: <\/strong><\/p>\n<p><em>Access &#038; Reimbursement<\/em> reports provide in-depth insight regarding the impact of payer policies on physician prescribing behavior so that clients can build their market access strategy and optimize their brand positioning.<\/p>\n<p><strong>Content Highlights:<\/strong><\/p>\n<p>Actionable recommendations to optimize market access, market access success and stumbles, market access roadblocks, reimbursement dynamics, the impact of pricing and reimbursement, policy, and coverage on prescribing.<\/p>\n<p><strong>Scope of Report:<\/strong><\/p>\n<ul>\n<li><em>Geography: <\/em> France, Germany, Italy, Spain, and the United Kingdom (i.e., EU5).<\/li>\n<li><em>Primary research: <\/em>Survey of 250 medical oncologists in the EU5 (50 per country) and interviews with 10 EU5 payers (2 per country).<\/li>\n<li><em>Key drugs c<\/em><em>overed:<\/em> Opdivo, Keytruda, Tecentriq.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390632","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390632","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390632\/revisions"}],"predecessor-version":[{"id":576724,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390632\/revisions\/576724"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390632"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}